Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Vivo Bio Tech reported audited financial results for Q4 and year ended March 31, 2026. Standalone revenue grew 12.6% to Rs. 5,256.84 Lakhs from Rs. 4,667.25 Lakhs in FY2025. However, the company swung to a net loss of Rs. 193.61 Lakhs (standalone) and Rs. 170.88 Lakhs (consolidated) compared to profits of Rs. 757.07 Lakhs and Rs. 728.26 Lakhs respectively in FY2025, primarily due to higher tax expenses. The Board also reappointed Mr. Kalyan Ram Mangipudi as Whole-time Director for another 5 years from July 2026, subject to shareholder approval. The company approved material related party transactions and engaged a consultant for a proposed Scheme of Arrangement/Amalgamation. The auditor flagged unpaid statutory dues totaling Rs. 419.29 Lakhs including PF, ESI, Professional Tax, TDS, and Self-Assessment Tax.
Revenue growth is positive but the swing to loss and unpaid statutory dues are concerns for investors. The proposed amalgamation could be a future growth catalyst but requires shareholder approvals.